1 Suppliers
3 Customers
3 Debt Items
20 Related Chains
Search VIVS in the supply chain database
Create VIVS supply chain alerts
Read VIVS supply chain intel
ORANGE supply chain
NVIDIA Corporation supply chain
Amazon.com, Inc. supply chain
Johnson & Johnson supply chain
Suppliers 1
Clients 3
Debt 3
Acquisitions 0
Ownership 0
Secondary 20
VivoSim Labs, Inc. Suppliers
Ticker Name Confidence Evidence
VISCIENT VISCIENT
For the three and nine months ended December 31, 2025, the Company incurred $ 213,000 and $ 428,000 in R&D consulting expenses from Viscient, respectively.
VivoSim Labs, Inc. Customers
Ticker Name Confidence Evidence
VISCIENT VISCIENT
Additionally, for the three and nine months ended December 31, 2025 and 2024, the Company provided approximately $ 5,000 and $ 4,000 of histology services to Viscient, respectively.
LLY Eli Lilly and Company
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 37 PART III 38 Item 10. Directors, Executive Officers and Corporate Governance 38 Item 11. Executive Compensation 38 Item …
LLY Eli Lilly and Company
Reciprocal relationship from LLY graph: Reciprocal relationship from VIVS graph: Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 37 PART III 38 Item 10. Directors, Execut…
VivoSim Labs, Inc. Debt Obligations
Instrument Description Confidence Evidence
VIVS-DEBT-13373
Xbrl Convertible
xbrl convertible detail from xbrl 2014-03-31.
VIVS-DEBT
Debt stack $812,000
Market cache reports total debt of $812,000.
VIVS-DEBT-13372
Warrants outstanding: 8647
xbrl warrant detail from xbrl 2019-09-30.
VivoSim Labs, Inc. Acquisitions
No acquisitions on record No completed or pending acquisitions found in our database for VivoSim Labs, Inc..
VivoSim Labs, Inc. Ownership
No ownership data on record No major institutional ownership relationships found in our database for VivoSim Labs, Inc..
VivoSim Labs, Inc. Extended Supply Chain Network
Ticker Name Chain Index Hops Relationship Types
ACRS Aclaris Therapeutics, Inc.
100.00 2
VEEV Veeva Systems Inc.
100.00 2
BYSI BeyondSpring Inc.
100.00 2
ACIU AC Immune SA
100.00 2
VNDA Vanda Pharmaceuticals Inc.
100.00 2
CRIS Curis, Inc.
100.00 2
ALEC Alector, Inc.
100.00 2
DSGN Design Therapeutics, Inc.
100.00 2
AXSM Axsome Therapeutics, Inc.
100.00 2
EDSA Edesa Biotech, Inc.
100.00 2
BIOA BioAge Labs, Inc.
100.00 2
CTNM Contineum Therapeutics, Inc.
100.00 2
FHTX Foghorn Therapeutics Inc.
100.00 2
FDMT 4D Molecular Therapeutics, Inc.
100.00 2
NVO Novo Nordisk A/S
100.00 2
DAWN Day One Biopharmaceuticals Inc
100.00 2
SDGR Schrödinger, Inc.
100.00 2
ALNY Alnylam Pharmaceuticals, Inc.
100.00 2
AKTS Aktis Oncology, Inc.
100.00 2
IMNM Immunome, Inc.
100.00 2
